18:28:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017


ListaOB Match
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2023-03-22 13:52:27
Moss, 22 March 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, is pleased to announce the results from a study on health economic impact
of use of GCAL¬ģ Calprotectin Immunoassay for early detection of infection in
intensive care patients. The study has been presented at the International
Symposium on Intensive Care and Emergency Medicine (ISICEM) meeting in Brussels
which is currently ongoing.

A health economic model has been developed, based on the results from a previous
study showing the ability of calprotectin to detect bacterial infections before
onset of clinical symptoms and antibiotic prescription1.

The model was employed to estimate the cost-effectiveness of analysis of
calprotectin for early detection of bacterial infection and thus, the earlier
start of antibiotic treatment compared to other diagnostic biomarkers. The
base-case results show that predictively measuring of calprotectin in an
intensive care unit (ICU) setting, using the GCAL¬ģ Calprotectin assay, reduces
total costs by approximately 13 000 - 18 000 EUR per patient, overall mortality
rate by 0.11, and mean length of stay in an ICU and general ward by 1.3 - 2 days
and 6.9 - 8 days, respectively. Compared to procalcitonin (PCT), C-reactive
protein (CRP) and white blood cell count (WBC), calprotectin, analysed by the
GCAL¬ģ Calprotectin Immunoassay, was shown to save total costs, reduce the mean
duration of in-patient care, and reduce in-hospital mortality in those patients.

Although the study focuses on a health economic perspective, the main rationale
of analysis of calprotectin is from a clinical perspective, since early
diagnosis of severe infections and sepsis reduces both delays in treatment and
mortality. From this aspect, data from the health economic model support
previous studies, where early detection of severe infections and sepsis has both
cost-saving and life-saving impact in the ICU setting.

For further information please see the enclosed study poster.

IR Contact:
Njaal Kind, CFO
+47 919 06 525 (mobile)

Reference: 1. Jonsson, N. et al., Calprotectin as an early biomarker of
bacterial infections in critically ill patients: an exploratory cohort
assessment. Crit Care Resusc. 2017 19, 205-213.